Web of Science

Permanent URI for this collectionhttps://hdl.handle.net/11452/19318

Browse

Browsing by BUU Author "Açıkgöz, Ebru"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Publication
    Correlates of visceral and subcutaneous fat thickness in non-diabetic obese and morbidly obese patients
    (Carbone Editore, 2017) Şeker, İsmail; Gül, Özen Öz; Pekgöz, Murat; Güllülü, Sümeyye; Cander, Soner; Tutuncu, Ahmet; Sağ, Saim; Açıkgöz, Ebru; Sarandol, Emre; Ersoy, Canan; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Kardiyoloji Anabilim Dalı.; 0000-0002-2593-7196; 0000-0001-8404-8252; AAH-8861-2021; ABE-1716-2020; AAW-9185-2020; AAI-1005-2021; 26040787100; 36010142900; 57204660708; 25027068600; 7004229025; 12140008100; 56328183700; 55943324800; 6701485882
    Background: To determine the correlates of visceral and subcutaneous fat thickness in non-diabetic obese and morbidly obese patients Methods: A total of 31 obese female outpatients composed of morbidly obese (n=16, BMI of >= 40kg/m(2)) and obese (n=15, BMI of 30-39.9kg/m(2)) patients were included in the present study. Data on age, anthropometrics, blood biochemistry, HOMA-IR, carotid intima-media thickness (CIMT) were recorded in each subject as were plasma resistin (mu g/L) and visfatin (mu g/ml) levels, epicardial, subcutaneous and abdominal fat thickness (mm). Correlates of visceral and subcutaneous fat thickness were determined via linear regression models with inclusion of severity of obesity, insulin resistance, plasma resistin and visfatin levels and CIMT as variables. Results: Epicardial fat thickness (mm) was 3.1(1.0-10.20) and 8.8(2.60-13.0), CIMT (mm) was 5.8(4.7-8.9) and 5.9(4-8.6), abdominal fat thickness (mm) was 10.8(7.8-16.1) and 13.2(8.7-16.5), subcutaneous fat thickness(mm) was 43.8(28.4-62.9) and 57.4(39.5-72.7), plasma resistin levels (mu g/L) were 8.5(4.7-38.1) and 10.8(0.7-26.4) and plasma visfatin levels (mu g/ml) were 55.5(5.1-209.5) and 78.2(4.7-228) in obese and morbidly obese patients, respectively. Linear regression analysis revealed that being morbidly obese was likely to increase epicardial fat thickness by 4.33mm(p=0.004) compared with obesity, while for each 1 unit increase in HOMA levels, subcutaneous fat thickness was likely to decrease by 1.16mm(p=0.009). Conclusion: In conclusion, our findings revealed that neither plasma levels for resistin and visfatin nor CIMT correlated with visceral or subcutaneous fat thickness in non-diabetic obese females, while increase in subcutaneous and epicardial fat thickness values were noted with decrease in HOMA-IR and the presence of morbid obesity, respectively.
  • No Thumbnail Available
    Publication
    Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome
    (John Libbey Eurotext, 2015-10-01) Cander, Soner; Gül, Bülent; Gül, Özen Öz; Açıkgöz, Ebru; Sarandöl, Emre; Ersoy, Canan; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; 0000-0002-2593-7196; AAI-1005-2021; JLB-9964-2023; ABE-1716-2020; AAH-8861-2021; 26040787100; 56328183700; 55943324800; 6701485882
    This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS). A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age: 29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.
  • No Thumbnail Available
    Publication
    The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure
    (Taylor & Francis, 2015-05-12) Beşli, Feyzullah; Güllülü, Sümeyye; Sağ, Saim; Keçebaş, Mesut; Açıkgöz, Ebru; Sarandöl, Emre; Aydınlar, Ali; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0002-8974-8837; 0000-0001-8404-8252; 0000-0002-2593-7196; AAI-6632-2021; AAW-9185-2020; ABE-1716-2020; 35767335000; 57204660708; 12140008100; 36198369900; 56328183700; 55943324800; 6603131517
    Objectives Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) appears to be involved in atherosclerotic plaque vulnerability and rupture. In this study, we aimed to evaluate the utility of serum LOX-1 levels in the diagnosis and assessment of left ventricular systolic HF and LOX-1's relationship with serum pro-brain natriuretic peptide (NT-proBNP). Design and settings This was a cross-sectional study of all eligible patients admitted to the department of cardiology of the University Hospital between July 2011 and April 2012. Methods Fifty-five patients with a diagnosis of systolic heart failure and 25 patients without systolic HF were enrolled in this study. Serum C-reactive protein, NT-proBNP, and LOX-1 were studied. Results Serum LOX-1 and NT-proBNP levels were significantly higher in the heart failure group and showed a positive correlation with NT-proBNP and negative correlations with left ventricular ejection fraction (EF). In addition, LOX-1 levels in patients with ischaemic cardiomyopathy were significantly higher, while they were similar in patients with dilated cardiomyopathy compared to control subjects. Conclusion Our study demonstrates the utility of the serum LOX-1 levels in the diagnosis of left ventricular systolic heart failure. LOX-1 may have a place in the diagnosis of heart failure, in particular in patients with ischaemic cardiomyopathy.
  • No Thumbnail Available
    Publication
    Serum fetuin-A levels in patients with systolic heart failure
    (Taylor & Francis Ltd, 2014-05-05) Keçebaş, Mesut; Güllülü, Sümeyye; Saǧ, Saim; Beşli, Feyzullah; Açıkgöz, Ebru; Sarandöl, Emre; Aydınlar, Ali Altun; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0002-2593-7196; 0000-0001-8404-8252; 0000-0002-8974-8837; ABE-1716-2020; AAW-9185-2020; AAI-6632-2021; 36198369900; 57204660708; 12140008100; 35767335000; 56328183700; 55943324800; 6603131517
    Objective Inflammation and dystrophic calcification have been associated with cardiovascular disease (CVD) and chronic heart failure (CHF). The aim of the present study was to investigate the potential usefulness of fetuin-A as a biomarker in CHF. Methods Serum fetuin-A was measured in 66 CHF patients with left ventricular function < 50% and in 31 healthy controls at baseline. Fetuin-A was evaluated as a diagnostic marker for systolic heart failure and compared with C-reactive protein (CRP) and pro-brain natriuretic peptide (pro-BNP). Results The levels of serum fetuin-A were significantly decreased in the CHF patients compared to the control group (P < 0.01). Although there were significant correlations between fetuin-A and certain parameters in patients and controls, none of these were present consistently in either group. It was found that serum fetuin-A levels could identify patients with systolic heart failure with a high degree of sensitivity and specificity. Conclusions Serum fetuin-A is decreased in CHF patients, indicating that anti-inflammatory activity is downregulated in CHF and that calcification may be associated with CHF.